141 related articles for article (PubMed ID: 30406944)
21. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Brynes RK; Orazi A; Theodore D; Burgess P; Bailey CK; Thein MM; Bakshi KK
Am J Hematol; 2015 Jul; 90(7):598-601. PubMed ID: 25801698
[TBL] [Abstract][Full Text] [Related]
23. Eltrombopag induces major non-toxic hypersiderraemia.
Caillon H; Peterlin P; Chevallier P; Guillaume T; Lebourgeois A; Garnier A; Ropert-Bouchet M; Dejoie T
Br J Haematol; 2019 Jul; 186(2):365-366. PubMed ID: 30873599
[No Abstract] [Full Text] [Related]
24. Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Kazemi T; Martin S; Worswick S
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617608
[TBL] [Abstract][Full Text] [Related]
25. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation.
Pecci A; Barozzi S; d'Amico S; Balduini CL
Thromb Haemost; 2012 Jun; 107(6):1188-9. PubMed ID: 22398565
[No Abstract] [Full Text] [Related]
26. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685
[TBL] [Abstract][Full Text] [Related]
27. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
Huan Ng C; Jang-Milligan F; Schultz KR
Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932
[No Abstract] [Full Text] [Related]
28. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
29. Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Mulla CM; Rashidi A; Levitov AB
Platelets; 2014; 25(2):144-6. PubMed ID: 23320857
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
González-López TJ; Fernández-Fuertes F; Hernández-Rivas JA; Sánchez-González B; Martínez-Robles V; Alvarez-Román MT; Pérez-Rus G; Pascual C; Bernat S; Arrieta-Cerdán E; Aguilar C; Bárez A; Peñarrubia MJ; Olivera P; Fernández-Rodríguez A; de Cabo E; García-Frade LJ; González-Porras JR
Int J Hematol; 2017 Oct; 106(4):508-516. PubMed ID: 28667351
[TBL] [Abstract][Full Text] [Related]
31. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Bussel JB; Saleh MN; Vasey SY; Mayer B; Arning M; Stone NL
Br J Haematol; 2013 Feb; 160(4):538-46. PubMed ID: 23278590
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
[TBL] [Abstract][Full Text] [Related]
33. Eltrombopag: a novel oral thrombopoietin receptor agonist.
Corman SL; Mohammad RA
Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
Ramadan H; Duong VH; Al Ali N; Padron E; Zhang L; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S64-6. PubMed ID: 27521328
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Kellum A; Jagiello-Gruszfeld A; Bondarenko IN; Patwardhan R; Messam C; Mostafa Kamel Y
Curr Med Res Opin; 2010 Oct; 26(10):2339-46. PubMed ID: 20735290
[TBL] [Abstract][Full Text] [Related]
36. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Gudbrandsdottir S; Frederiksen H; Hasselbalch H
Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
[TBL] [Abstract][Full Text] [Related]
38. [Case report; a thromboembolic event in a patient with antiphospholipid antibody associated thrombocytopenia during eltrombopag therapy].
Kanda M; Kondo M; Yamamoto S; Mukai M
Nihon Naika Gakkai Zasshi; 2013 Jun; 102(6):1461-3. PubMed ID: 23947214
[No Abstract] [Full Text] [Related]
39. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
[No Abstract] [Full Text] [Related]
40. Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag.
Sperati CJ; Streiff MB
Am J Hematol; 2010 Sep; 85(9):724-6. PubMed ID: 20652968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
